Amylyx Pharmaceuticals (AMLX) Financials

$3.98 +0.16 (+4.19%)

Closing price 04/17/2025 04:00 PM Eastern

Extended Trading

$3.98 0.00 (-0.13%)

As of 04/17/2025 04:07 PM Eastern

Annual Income Statements for Amylyx Pharmaceuticals

This table shows Amylyx Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-198	49	-302
Consolidated Net Income / (Loss)	-198	49	-302
Net Income / (Loss) Continuing Operations	-198	49	-302
Total Pre-Tax Income	-198	54	-302
Total Operating Income	-201	39	-315
Total Gross Profit	19	355	81
Total Revenue	22	381	87
Operating Revenue	22	381	87
Total Cost of Revenue	2.99	25	5.95
Operating Cost of Revenue	2.99	25	5.95
Total Operating Expenses	221	317	396
Selling, General & Admin Expense	127	188	114
Research & Development Expense	93	128	140
Other Operating Expenses / (Income)	-	0.00	119
Restructuring Charge	-	0.00	23
Total Other Income / (Expense), net	3.74	15	13
Interest & Investment Income	4.29	16	14
Other Income / (Expense), net	-0.55	-0.66	-1.21
Income Tax Expense	0.77	5.03	-0.39
Basic Earnings per Share	($3.39)	$0.73	($4.43)
Weighted Average Basic Shares Outstanding	58.50M	67.23M	68.14M
Diluted Earnings per Share	($3.39)	$0.70	($4.43)
Weighted Average Diluted Shares Outstanding	58.50M	69.99M	68.14M
Weighted Average Basic & Diluted Shares Outstanding	66.72M	67.78M	88.60M

This table shows Amylyx Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-54	-43	1.57	22	21	4.73	-119	-73	-73	-38
Consolidated Net Income / (Loss)	-54	-43	1.57	22	21	4.73	-119	-73	-73	-38
Net Income / (Loss) Continuing Operations	-54	-43	1.57	22	21	4.73	-119	-73	-73	-38
Total Pre-Tax Income	-54	-42	1.40	24	22	6.48	-119	-73	-73	-38
Total Operating Income	-55	-45	-2.05	20	19	1.93	-122	-76	-76	-41
Total Gross Profit	0.17	19	66	93	97	99	83	-1.03	0.42	-0.67
Total Revenue	0.35	22	71	98	103	108	89	-1.02	0.42	-0.67
Operating Revenue	0.35	22	71	98	103	108	89	-1.02	0.42	-0.67
Total Operating Expenses	55	64	68	72	79	97	205	75	76	40
Selling, General & Admin Expense	30	41	44	43	49	52	58	22	18	17
Research & Development Expense	25	23	24	29	30	45	37	23	57	23
Total Other Income / (Expense), net	0.80	2.47	3.46	3.81	3.69	4.54	3.58	3.59	2.96	2.47
Interest & Investment Income	0.60	3.16	3.72	3.89	4.18	4.37	4.33	4.07	3.10	2.32
Other Income / (Expense), net	0.20	-0.69	-0.26	-0.08	-0.49	0.17	-0.75	-0.48	-0.14	0.16
Income Tax Expense	-0.13	0.58	-0.17	1.93	1.52	1.75	0.24	0.00	0.00	-0.64
Basic Earnings per Share	($0.92)	($0.61)	$0.02	$0.33	$0.31	$0.07	($1.75)	($1.07)	($1.07)	($0.54)
Weighted Average Basic Shares Outstanding	58.53M	58.50M	66.72M	67.23M	67.41M	67.23M	67.85M	68.02M	68.09M	68.14M
Diluted Earnings per Share	($0.92)	($0.61)	$0.02	$0.31	$0.30	$0.07	($1.75)	($1.07)	($1.07)	($0.54)
Weighted Average Diluted Shares Outstanding	58.53M	58.50M	70.86M	70.13M	69.75M	69.99M	67.85M	68.02M	68.09M	68.14M
Weighted Average Basic & Diluted Shares Outstanding	66.26M	66.72M	67.18M	67.38M	67.52M	67.78M	68.01M	68.08M	68.55M	88.60M

This table details how cash moves in and out of Amylyx Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Change in Cash & Equivalents	13	108	-92
Net Cash From Operating Activities	-180	12	-168
Net Cash From Continuing Operating Activities	-180	12	-168
Net Income / (Loss) Continuing Operations	-198	49	-302
Consolidated Net Income / (Loss)	-198	49	-302
Depreciation Expense	0.49	1.09	0.90
Amortization Expense	-2.06	-9.94	-9.86
Non-Cash Adjustments To Reconcile Net Income	23	37	189
Changes in Operating Assets and Liabilities, net	-3.28	-66	-46
Net Cash From Investing Activities	-239	92	76
Net Cash From Continuing Investing Activities	-239	92	76
Purchase of Property, Plant & Equipment	-2.53	-1.24	-0.16
Acquisitions	-	0.00	-36
Purchase of Investments	-416	-301	-232
Sale and/or Maturity of Investments	179	394	344
Net Cash From Financing Activities	432	3.54	0.35
Net Cash From Continuing Financing Activities	432	3.54	0.35
Other Financing Activities, net	231	3.54	0.35
Effect of Exchange Rate Changes	-0.07	0.16	-0.44
Cash Income Taxes Paid	0.03	6.39	0.71

This table details how cash moves in and out of Amylyx Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	41	-45	52	133	-113	35	0.35	-96	-2.44	5.56
Net Cash From Operating Activities	-43	-50	-5.07	8.61	-5.17	14	-0.49	-67	-42	-59
Net Cash From Continuing Operating Activities	-43	-50	-5.07	8.61	-5.17	14	-0.49	-67	-42	-59
Net Income / (Loss) Continuing Operations	-54	-43	1.57	22	21	4.73	-119	-73	-73	-38
Consolidated Net Income / (Loss)	-54	-43	1.57	22	21	4.73	-119	-73	-73	-38
Depreciation Expense	0.17	0.18	0.20	0.28	0.30	0.30	0.32	0.21	0.22	0.16
Amortization Expense	-0.09	-1.86	-2.90	-1.98	-2.48	-2.57	-2.58	-3.18	-2.31	-1.79
Non-Cash Adjustments To Reconcile Net Income	6.14	6.54	7.94	10	11	8.20	121	18	44	5.42
Changes in Operating Assets and Liabilities, net	4.66	-12	-12	-22	-35	2.89	-0.31	-9.18	-11	-25
Net Cash From Investing Activities	84	-228	56	123	-108	21	0.82	-29	39	65
Net Cash From Continuing Investing Activities	84	-228	56	123	-108	21	0.82	-29	39	65
Purchase of Property, Plant & Equipment	-0.46	-0.62	-0.25	-0.28	-0.36	-0.36	-0.07	-0.09	0.02	-0.02
Sale and/or Maturity of Investments	85	34	66	124	57	148	74	130	75	65
Net Cash From Financing Activities	-	232	1.04	1.38	0.89	0.23	0.13	0.03	0.08	0.11
Net Cash From Continuing Financing Activities	-1.52	232	1.04	1.38	0.89	0.23	0.13	0.03	0.08	0.11
Other Financing Activities, net	-1.52	232	1.04	1.38	0.89	0.23	0.13	0.03	0.08	0.11
Effect of Exchange Rate Changes	-0.37	0.51	0.08	-0.02	-0.13	0.24	-0.11	-0.04	0.24	-0.53
Cash Income Taxes Paid	-0.03	0.05	0.00	-2.56	-2.42	11	-0.28	-0.01	0.02	0.97

This table presents Amylyx Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Total Assets	391	517	194
Total Current Assets	382	465	189
Cash & Equivalents	63	170	77
Short-Term Investments	284	201	99
Accounts Receivable	15	40	0.45
Inventories, net	9.77	38	0.00
Prepaid Expenses	10	15	12
Plant, Property, & Equipment, net	2.61	2.69	0.96
Total Noncurrent Assets	6.71	50	3.24
Other Noncurrent Operating Assets	6.71	50	3.24
Total Liabilities & Shareholders' Equity	391	517	194
Total Liabilities	51	84	29
Total Current Liabilities	47	82	28
Accounts Payable	6.26	22	2.94
Accrued Expenses	38	58	24
Other Current Liabilities	2.04	2.26	1.52
Total Noncurrent Liabilities	4.24	1.98	0.46
Noncurrent Deferred Revenue	0.00	0.00	0.00
Other Noncurrent Operating Liabilities	4.24	1.98	0.46
Commitments & Contingencies	0.00	0.00	0.00
Redeemable Noncontrolling Interest	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	341	433	165
Total Preferred & Common Equity	341	433	165
Preferred Stock	0.00	0.00	0.00
Total Common Equity	341	433	165
Common Stock	695	738	772
Retained Earnings	-354	-305	-607
Accumulated Other Comprehensive Income / (Loss)	-0.09	0.20	-0.09

This table presents Amylyx Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	181	408	454	467	417	332	251
Total Current Assets	172	389	427	434	411	327	245
Cash & Equivalents	108	115	248	135	171	75	72
Short-Term Investments	55	231	110	220	203	235	163
Accounts Receivable	0.14	18	33	29	20	4.09	1.73
Inventories, net	0.56	13	25	32	0.00	0.00	0.00
Prepaid Expenses	8.34	13	12	17	17	13	9.14
Plant, Property, & Equipment, net	2.12	2.56	2.64	2.76	2.46	1.47	1.25
Total Noncurrent Assets	7.13	16	24	30	4.46	3.97	4.20
Other Noncurrent Operating Assets	7.13	16	24	30	4.46	3.97	4.20
Total Liabilities & Shareholders' Equity	181	408	454	467	417	332	251
Total Liabilities	37	55	67	48	93	71	55
Total Current Liabilities	33	52	64	46	92	70	54
Accounts Payable	7.05	11	25	6.37	21	4.96	1.49
Accrued Expenses	24	39	37	37	68	63	50
Other Current Liabilities	1.99	2.09	2.15	2.20	2.31	2.37	1.97
Total Noncurrent Liabilities	4.77	3.69	3.14	2.57	1.38	0.77	0.60
Other Noncurrent Operating Liabilities	4.77	3.69	3.14	2.57	1.38	0.77	0.60
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	144	353	386	418	324	261	196
Total Preferred & Common Equity	144	353	386	418	324	261	196
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	144	353	386	418	324	261	196
Common Stock	456	705	717	728	748	758	765
Retained Earnings	-312	-353	-331	-310	-424	-496	-569
Accumulated Other Comprehensive Income / (Loss)	-0.73	0.03	-0.07	-0.15	-0.08	-0.10	0.64

This table displays calculated financial ratios and metrics derived from Amylyx Pharmaceuticals' official financial filings.

Metric	2022	2023	2024
Growth Metrics	-	-	-
Revenue Growth	7,700.00%	1,612.94%	-77.06%
EBITDA Growth	-131.75%	114.40%	-1,209.24%
EBIT Growth	-129.51%	118.89%	-928.34%
NOPAT Growth	-143.49%	124.98%	-725.70%
Net Income Growth	-125.60%	124.84%	-712.42%
EPS Growth	74.61%	120.65%	-732.86%
Operating Cash Flow Growth	-140.47%	106.63%	-1,506.55%
Free Cash Flow Firm Growth	0.00%	76.71%	-341.31%
Invested Capital Growth	20.13%	1,079.33%	-118.91%
Revenue Q/Q Growth	6,343.48%	29.42%	-55.53%
EBITDA Q/Q Growth	-6.32%	267.33%	-14.83%
EBIT Q/Q Growth	-5.37%	512.57%	-15.59%
NOPAT Q/Q Growth	-8.80%	1,514.06%	-15.65%
Net Income Q/Q Growth	-7.80%	2,583.61%	-16.29%
EPS Q/Q Growth	51.36%	3,400.00%	-15.97%
Operating Cash Flow Q/Q Growth	-13.54%	123.22%	-76.31%
Free Cash Flow Firm Q/Q Growth	0.00%	60.67%	-64.70%
Invested Capital Q/Q Growth	65.86%	-2.03%	69.27%
Profitability Metrics	-	-	-
Gross Margin	86.54%	93.32%	93.19%
EBITDA Margin	-915.25%	7.69%	-371.86%
Operating Margin	-905.72%	10.19%	-360.22%
EBIT Margin	-908.20%	10.02%	-361.61%
Profit (Net Income) Margin	-892.38%	12.94%	-345.36%
Tax Burden Percent	100.39%	90.74%	99.87%
Interest Burden Percent	97.87%	142.35%	95.63%
Effective Tax Rate	0.00%	9.26%	0.00%
Return on Invested Capital (ROIC)	0.00%	126.36%	-875.40%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	122.44%	-845.67%
Return on Net Nonoperating Assets (RNNOA)	0.00%	-113.62%	774.52%
Return on Equity (ROE)	-92.53%	12.73%	-100.88%
Cash Return on Invested Capital (CROIC)	0.00%	-53.48%	0.00%
Operating Return on Assets (OROA)	-81.23%	8.39%	-88.86%
Return on Assets (ROA)	-79.82%	10.84%	-84.87%
Return on Common Equity (ROCE)	-40.88%	12.73%	-100.88%
Return on Equity Simple (ROE_SIMPLE)	-58.24%	11.37%	-183.14%
Net Operating Profit after Tax (NOPAT)	-141	35	-220
NOPAT Margin	-634.00%	9.25%	-252.16%
Net Nonoperating Expense Percent (NNEP)	-25.93%	3.92%	-29.73%
Return On Investment Capital (ROIC_SIMPLE)	-	8.12%	-133.71%
Cost of Revenue to Revenue	13.46%	6.68%	6.81%
SG&A Expenses to Revenue	571.88%	49.47%	130.86%
R&D to Revenue	420.38%	33.66%	160.56%
Operating Expenses to Revenue	992.25%	83.13%	453.41%
Earnings before Interest and Taxes (EBIT)	-202	38	-316
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-203	29	-325
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	7.19	2.29	1.57
Price to Tangible Book Value (P/TBV)	7.19	2.29	1.57
Price to Revenue (P/Rev)	110.13	2.61	2.97
Price to Earnings (P/E)	0.00	20.17	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	4.96%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	10.03	0.00
Enterprise Value to Revenue (EV/Rev)	94.52	1.63	0.95
Enterprise Value to EBITDA (EV/EBITDA)	0.00	21.25	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	16.32	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	17.68	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	52.23	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-1.03	-0.93	-0.92
Leverage Ratio	1.16	1.17	1.19
Compound Leverage Factor	1.13	1.67	1.14
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	27.01	8.14	-2.94
Noncontrolling Interest Sharing Ratio	55.82%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	8.20	5.66	6.67
Quick Ratio	7.77	5.01	6.23
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-143	-33	-147
Operating Cash Flow to CapEx	-7,120.78%	960.44%	-106,781.53%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.09	0.84	0.25
Accounts Receivable Turnover	0.00	13.76	4.31
Inventory Turnover	0.00	1.06	0.00
Fixed Asset Turnover	14.41	143.77	47.91
Accounts Payable Turnover	0.56	1.80	0.48
Days Sales Outstanding (DSO)	0.00	26.53	84.59
Days Inventory Outstanding (DIO)	0.00	344.99	0.00
Days Payable Outstanding (DPO)	648.11	203.14	766.42
Cash Conversion Cycle (CCC)	-648.11	168.38	-681.83
Capital & Investment Metrics	-	-	-
Invested Capital	-6.34	62	-12
Invested Capital Turnover	-3.12	13.66	3.47
Increase / (Decrease) in Invested Capital	1.60	68	-74
Enterprise Value (EV)	2,101	622	83
Market Capitalization	2,448	994	259
Book Value per Share	$5.14	$6.42	$2.40
Tangible Book Value per Share	$5.14	$6.42	$2.40
Total Capital	341	433	165
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-347	-371	-177
Capital Expenditures (CapEx)	2.53	1.24	0.16
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-11	11	-15
Debt-free Net Working Capital (DFNWC)	336	383	161
Net Working Capital (NWC)	336	383	161
Net Nonoperating Expense (NNE)	57	-14	81
Net Nonoperating Obligations (NNO)	-347	-371	-177
Total Depreciation and Amortization (D&A)	-1.57	-8.85	-8.95
Debt-free, Cash-free Net Working Capital to Revenue	-51.38%	2.96%	-17.71%
Debt-free Net Working Capital to Revenue	1,509.33%	100.48%	184.30%
Net Working Capital to Revenue	1,509.33%	100.48%	184.30%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($3.39)	$0.73	($4.43)
Adjusted Weighted Average Basic Shares Outstanding	58.50M	67.23M	68.14M
Adjusted Diluted Earnings per Share	($3.39)	$0.70	($4.43)
Adjusted Weighted Average Diluted Shares Outstanding	58.50M	69.99M	68.14M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	66.72M	67.78M	88.60M
Normalized Net Operating Profit after Tax (NOPAT)	-141	35	-204
Normalized NOPAT Margin	-634.00%	9.25%	-233.85%
Pre Tax Income Margin	-888.89%	14.26%	-345.81%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Amylyx Pharmaceuticals' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	21.05%	0.00%	0.00%	0.00%	29,666.09%	395.54%	24.10%	-101.04%	-99.59%	-100.61%
EBITDA Growth	-135.40%	-34.66%	89.51%	133.92%	129.50%	99.65%	-2,395.89%	-532.94%	-585.21%	-25,278.31%
EBIT Growth	-135.39%	-29.40%	95.16%	137.06%	133.46%	104.65%	-5,207.86%	-481.56%	-515.76%	-2,023.85%
NOPAT Growth	-138.59%	-57.49%	93.12%	148.91%	145.59%	104.53%	-3,614.16%	-387.49%	-403.48%	-2,114.18%
Net Income Growth	-132.29%	-50.66%	103.29%	140.83%	138.87%	111.08%	-7,652.00%	-429.35%	-447.98%	-893.62%
EPS Growth	73.10%	85.44%	102.15%	133.33%	132.61%	111.48%	-8,850.00%	-445.16%	-456.67%	-871.43%
Operating Cash Flow Growth	-106.46%	-75.96%	87.52%	118.53%	88.00%	127.27%	90.36%	-873.38%	-704.22%	-535.45%
Free Cash Flow Firm Growth	0.00%	0.00%	-22.51%	-1.33%	-227.05%	-104.18%	-26.03%	199.12%	175.36%	167.69%
Invested Capital Growth	0.00%	20.13%	148.91%	309.39%	441.26%	1,079.33%	-800.56%	-266.74%	-160.28%	-118.91%
Revenue Q/Q Growth	0.00%	6,243.48%	226.38%	37.50%	4.56%	5.61%	-18.26%	-101.15%	140.66%	-259.86%
EBITDA Q/Q Growth	-0.20%	13.69%	89.32%	467.33%	-12.85%	-101.03%	-75,287.95%	36.28%	2.32%	45.91%
EBIT Q/Q Growth	-0.34%	16.89%	94.89%	969.11%	-9.38%	-88.45%	-5,937.39%	37.52%	1.26%	46.58%
NOPAT Q/Q Growth	-0.79%	18.45%	92.63%	906.97%	-6.04%	-91.90%	-6,150.87%	37.54%	0.82%	46.27%
Net Income Q/Q Growth	0.58%	20.56%	103.68%	1,303.31%	-5.35%	-77.36%	-2,610.95%	38.80%	-0.01%	48.36%
EPS Q/Q Growth	1.08%	33.70%	103.28%	1,450.00%	-3.23%	-76.67%	-2,600.00%	38.86%	0.00%	49.53%
Operating Cash Flow Q/Q Growth	7.28%	-15.37%	89.79%	269.74%	-160.04%	362.16%	-103.61%	-13,515.54%	37.56%	-41.95%
Free Cash Flow Firm Q/Q Growth	18.16%	-66.46%	28.27%	-3.70%	-164.14%	-3.92%	55.73%	181.56%	100.83%	-6.66%
Invested Capital Q/Q Growth	-33.64%	65.86%	210.03%	317.11%	117.80%	-2.03%	-178.71%	0.72%	21.26%	69.27%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	50.14%	87.11%	92.60%	94.32%	94.92%	91.37%	93.29%	0.00%	100.00%	0.00%
EBITDA Margin	-15,769.86%	-214.58%	-7.02%	18.75%	15.63%	-0.15%	-141.18%	0.00%	-18,722.60%	0.00%
Operating Margin	-15,849.57%	-203.76%	-2.87%	20.57%	18.23%	1.78%	-137.78%	0.00%	-18,187.74%	0.00%
EBIT Margin	-15,791.88%	-206.91%	-3.24%	20.49%	17.75%	1.94%	-138.62%	0.00%	-18,221.63%	0.00%
Profit (Net Income) Margin	-15,581.45%	-195.13%	2.20%	22.48%	20.35%	4.36%	-134.01%	0.00%	-17,476.92%	0.00%
Tax Burden Percent	99.77%	101.37%	112.12%	91.95%	93.23%	73.05%	100.20%	100.00%	100.00%	98.34%
Interest Burden Percent	98.90%	93.03%	-60.60%	119.32%	122.92%	307.65%	96.48%	94.70%	95.91%	94.28%
Effective Tax Rate	0.00%	0.00%	-12.12%	8.05%	6.77%	26.95%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	477.55%	223.27%	17.80%	0.00%	0.00%	-198,826.27%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	476.31%	221.94%	16.88%	0.00%	0.00%	-198,819.57%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	-463.81%	-204.27%	-15.66%	0.00%	0.00%	190,679.53%	0.00%
Return on Equity (ROE)	-127.76%	-92.53%	-50.19%	13.74%	19.00%	2.14%	-21.00%	-51.22%	-8,146.74%	0.00%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	-1,866.06%	-342.98%	-133.23%	-53.48%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-30.03%	-18.51%	-0.89%	11.58%	16.12%	1.63%	-133.68%	0.00%	-9,982.69%	0.00%
Return on Assets (ROA)	-29.63%	-17.45%	0.60%	12.71%	18.47%	3.66%	-129.24%	0.00%	-9,574.70%	0.00%
Return on Common Equity (ROCE)	-127.76%	-40.88%	-50.19%	13.74%	19.00%	2.14%	-21.00%	-51.22%	-8,146.74%	0.00%
Return on Equity Simple (ROE_SIMPLE)	-127.76%	0.00%	-42.24%	-18.85%	0.44%	0.00%	-21.91%	-63.48%	-132.24%	0.00%
Net Operating Profit after Tax (NOPAT)	-38	-31	-2.30	19	17	1.41	-85	-53	-53	-28
NOPAT Margin	-11,094.70%	-142.63%	-3.22%	18.91%	16.99%	1.30%	-96.44%	0.00%	-12,731.42%	0.00%
Net Nonoperating Expense Percent (NNEP)	-19.04%	-5.19%	1.29%	1.24%	1.33%	0.92%	-9.26%	-5.79%	-6.70%	-3.32%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	0.33%	-	-	-	-17.27%
Cost of Revenue to Revenue	49.86%	12.89%	7.40%	5.68%	5.08%	8.63%	6.71%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	8,678.26%	186.63%	61.61%	44.18%	47.44%	48.17%	65.16%	0.00%	4,285.58%	0.00%
R&D to Revenue	7,221.45%	104.24%	33.87%	29.57%	29.25%	41.41%	41.30%	0.00%	13,807.69%	0.00%
Operating Expenses to Revenue	15,899.71%	290.87%	95.48%	73.75%	76.69%	89.59%	231.07%	0.00%	18,287.74%	0.00%
Earnings before Interest and Taxes (EBIT)	-54	-45	-2.32	20	18	2.11	-123	-77	-76	-40
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-54	-47	-5.01	18	16	-0.17	-125	-80	-78	-42
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	11.44	7.19	5.55	3.75	2.95	2.29	0.59	0.49	1.12	1.57
Price to Tangible Book Value (P/TBV)	11.44	7.19	5.55	3.75	2.95	2.29	0.59	0.49	1.12	1.57
Price to Revenue (P/Rev)	4,775.97	110.13	20.90	7.55	4.19	2.61	0.48	0.43	1.12	2.97
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	671.94	20.17	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.15%	4.96%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	231.11	37.53	13.87	10.03	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	4,304.69	94.52	17.21	5.69	2.99	1.63	0.00	0.00	0.00	0.95
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	21.25	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	16.32	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	17.68	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	52.23	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.13	-1.03	-1.01	-0.97	-0.92	-0.93	-1.06	-1.03	-0.96	-0.92
Leverage Ratio	1.26	1.16	1.15	1.17	1.15	1.17	1.22	1.21	1.17	1.19
Compound Leverage Factor	1.25	1.08	-0.70	1.40	1.42	3.61	1.18	1.15	1.12	1.12
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	23.95	28.33	21.23	13.44	16.19	7.91	0.71	0.07	-0.05	1.76
Noncontrolling Interest Sharing Ratio	0.00%	55.82%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.27	8.20	7.54	6.67	9.52	5.66	4.48	4.66	4.55	6.67
Quick Ratio	4.98	7.77	7.04	6.10	8.43	5.01	4.30	4.48	4.38	6.23
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-20	-33	-24	-24	-64	-67	-30	24	49	45
Operating Cash Flow to CapEx	-9,385.19%	-8,015.65%	-2,028.80%	3,096.76%	-1,447.90%	3,806.46%	-729.85%	-74,808.99%	0.00%	-295,040.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.09	0.27	0.57	0.91	0.84	0.96	0.76	0.55	0.25
Accounts Receivable Turnover	2.52	0.00	0.00	0.00	19.95	13.76	21.00	15.91	12.64	4.31
Inventory Turnover	0.31	0.00	0.00	0.00	1.15	1.06	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.16	14.41	48.67	85.39	120.61	143.77	158.63	145.38	97.92	47.91
Accounts Payable Turnover	0.02	0.56	0.80	0.84	2.82	1.80	1.62	1.38	3.90	0.48
Days Sales Outstanding (DSO)	144.94	0.00	0.00	0.00	18.29	26.53	17.38	22.95	28.87	84.59
Days Inventory Outstanding (DIO)	1,194.74	0.00	0.00	0.00	318.01	344.99	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	14,965.00	648.11	459.01	432.17	129.60	203.14	225.29	263.56	93.65	766.42
Cash Conversion Cycle (CCC)	-13,625.32	-648.11	-459.01	-432.17	206.70	168.38	-207.91	-240.61	-64.78	-681.83
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-19	-6.34	6.97	29	63	62	-49	-49	-38	-12
Invested Capital Turnover	-0.04	-3.12	-25.71	25.25	13.14	13.66	-19.01	-30.78	15.62	3.47
Increase / (Decrease) in Invested Capital	-19	1.60	21	43	82	68	-56	-78	-102	-74
Enterprise Value (EV)	1,485	2,101	1,612	1,092	879	622	-182	-181	-14	83
Market Capitalization	1,648	2,448	1,957	1,449	1,234	994	192	129	221	259
Book Value per Share	$2.46	$5.14	$5.29	$5.75	$6.21	$6.42	$4.78	$3.84	$2.88	$2.40
Tangible Book Value per Share	$2.46	$5.14	$5.29	$5.75	$6.21	$6.42	$4.78	$3.84	$2.88	$2.40
Total Capital	144	341	353	386	418	433	324	261	196	165
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-163	-347	-346	-357	-355	-371	-373	-310	-234	-177
Capital Expenditures (CapEx)	0.46	0.62	0.25	0.28	0.36	0.36	0.07	0.09	-0.02	0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-23	-11	-8.24	6.04	33	11	-54	-53	-43	-15
Debt-free Net Working Capital (DFNWC)	140	336	337	363	388	383	319	257	191	161
Net Working Capital (NWC)	140	336	337	363	388	383	319	257	191	161
Net Nonoperating Expense (NNE)	15	11	-3.87	-3.50	-3.44	-3.32	33	19	20	9.09
Net Nonoperating Obligations (NNO)	-163	-347	-346	-357	-355	-371	-373	-310	-234	-177
Total Depreciation and Amortization (D&A)	0.08	-1.68	-2.70	-1.70	-2.18	-2.27	-2.27	-2.97	-2.08	-1.63
Debt-free, Cash-free Net Working Capital to Revenue	-6,678.55%	-51.38%	-8.79%	3.15%	11.37%	2.96%	-13.67%	-17.80%	-21.91%	-17.71%
Debt-free Net Working Capital to Revenue	40,449.86%	1,509.33%	360.29%	189.35%	132.04%	100.48%	80.12%	85.90%	97.39%	184.30%
Net Working Capital to Revenue	40,449.86%	1,509.33%	360.29%	189.35%	132.04%	100.48%	80.12%	85.90%	97.39%	184.30%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.92)	($0.61)	$0.02	$0.33	$0.31	$0.07	($1.75)	($1.07)	($1.07)	($0.54)
Adjusted Weighted Average Basic Shares Outstanding	58.53M	58.50M	66.72M	67.23M	67.41M	67.23M	67.85M	68.02M	68.09M	68.14M
Adjusted Diluted Earnings per Share	($0.92)	($0.61)	$0.02	$0.31	$0.30	$0.07	($1.75)	($1.07)	($1.07)	($0.54)
Adjusted Weighted Average Diluted Shares Outstanding	58.53M	58.50M	70.86M	70.13M	69.75M	69.99M	67.85M	68.02M	68.09M	68.14M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	66.26M	66.72M	67.18M	67.38M	67.52M	67.78M	68.01M	68.08M	68.55M	88.60M
Normalized Net Operating Profit after Tax (NOPAT)	-38	-31	-1.44	19	17	1.41	-85	-37	-53	-28
Normalized NOPAT Margin	-11,094.70%	-142.63%	-2.01%	18.91%	16.99%	1.30%	-96.44%	0.00%	-12,731.42%	0.00%
Pre Tax Income Margin	-15,617.68%	-192.48%	1.96%	24.44%	21.82%	5.97%	-133.74%	0.00%	-17,476.92%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Amylyx Pharmaceuticals' Financials

When does Amylyx Pharmaceuticals's fiscal year end?

According to the most recent income statement we have on file, Amylyx Pharmaceuticals' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Amylyx Pharmaceuticals' net income changed over the last 2 years?

Amylyx Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$301.74 million in 2024, rising from -$198.38 million in 2022. The previous period was $49.27 million in 2023.

What is Amylyx Pharmaceuticals's operating income?

Amylyx Pharmaceuticals's total operating income in 2024 was -$314.73 million, based on the following breakdown:

Total Gross Profit: $81.42 million
Total Operating Expenses: $396.15 million

How has Amylyx Pharmaceuticals revenue changed over the last 2 years?

Over the last 2 years, Amylyx Pharmaceuticals' total revenue changed from $22.23 million in 2022 to $87.37 million in 2024, a change of 293.0%.

How much debt does Amylyx Pharmaceuticals have?

Amylyx Pharmaceuticals' total liabilities were at $28.87 million at the end of 2024, a 65.6% decrease from 2023, and a 43.2% decrease since 2022.

How much cash does Amylyx Pharmaceuticals have?

In the past 2 years, Amylyx Pharmaceuticals' cash and equivalents has ranged from $62.53 million in 2022 to $170.20 million in 2023, and is currently $77.39 million as of their latest financial filing in 2024.

How has Amylyx Pharmaceuticals' book value per share changed over the last 2 years?

Over the last 2 years, Amylyx Pharmaceuticals' book value per share changed from 5.14 in 2022 to 2.40 in 2024, a change of -53.2%.

Related Companies

This page (NASDAQ:AMLX) was last updated on 4/18/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amylyx Pharmaceuticals (AMLX) Financials

Frequently Asked Questions About Amylyx Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amylyx Pharmaceuticals (AMLX) Financials

Annual Income Statements for Amylyx Pharmaceuticals

Quarterly Income Statements for Amylyx Pharmaceuticals

Annual Cash Flow Statements for Amylyx Pharmaceuticals

Quarterly Cash Flow Statements for Amylyx Pharmaceuticals

Annual Balance Sheets for Amylyx Pharmaceuticals

Quarterly Balance Sheets for Amylyx Pharmaceuticals

Annual Metrics and Ratios for Amylyx Pharmaceuticals

Quarterly Metrics and Ratios for Amylyx Pharmaceuticals

Frequently Asked Questions About Amylyx Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools